Advanced search
Publication Cover
Neuropsychiatric Disease and Treatment Volume 19, 2023 - Issue
Submit an article Journal homepage
327
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM

Robert Litman1 CBH Health LLC, Gaithersburg, MD, USA;2 Department of Psychiatry, Georgetown University Medical School, Washington, DC, USAORCID Iconhttps://orcid.org/0000-0002-8324-9658View further author information
ORCID Icon,
Dieter Naber3 Department of Psychiatry and Psychotherapy, Hamburg-Eppendorf University, Hamburg, GermanyView further author information
,
Lourdes Anta4 Medical Department, Laboratorios Farmacéuticos ROVI, S.A., Madrid, SpainORCID Iconhttps://orcid.org/0000-0001-5981-1850View further author information
ORCID Icon,
Javier Martínez4 Medical Department, Laboratorios Farmacéuticos ROVI, S.A., Madrid, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6314-4480View further author information
ORCID Icon,
Yuriy Filts5 Communal Noncommercial Enterprise of Lviv Regional Council, Lviv Regional Clinical Psychiatric Hospital, Lviv, UkraineORCID Iconhttps://orcid.org/0000-0001-8158-4332View further author information
ORCID Icon &
Christoph U Correll6 Department of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, NY, USA;7 Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA;8 Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin Berlin, Berlin, GermanyORCID Iconhttps://orcid.org/0000-0002-7254-5646View further author information
ORCID Icon
Pages 219-232 | Received 15 Nov 2022, Accepted 13 Jan 2023, Published online: 25 Jan 2023

Figures & data

Table 1 Patient Characteristics at Baseline in the Double Blind (DB) and Open-Label Extension (OLE) Phases

Figure 1 Mean (95% CI) change from baseline at each time point in Personal and Social Performance (PSP) total score during the double blind (DB) phase.

Notes: Mean (95% CI) PSP score at baseline for placebo = 50.5 (49; 52) and for Risperidone ISM = 49.9 (49; 51). P values are for Risperidone ISM group versus placebo (*p < 0.01; **p < 0.0001). Risperidone ISM group contains pooled data from Risperidone ISM 75 mg + Risperidone ISM 100 mg. Higher PSP scores indicate a better social functioning.
Abbreviations: CI, confidence interval; DB, double blind; PSP, Personal and Social Performance.
Figure 1 Mean (95% CI) change from baseline at each time point in Personal and Social Performance (PSP) total score during the double blind (DB) phase.

Figure 2 Mean domain scores of the Personal and Social Performance (PSP) scale at each assessment point during the double blind (DB) phase.

Notes: Graphs representing each of the 4 domain mean scores measured by the PSP scale. Smaller domain scores correspond to better functioning. P values are for Risperidone ISM group versus placebo (*p < 0.05; **p < 0.01; ***p < 0.0001). Risperidone ISM group contains pooled data from Risperidone ISM 75 mg + Risperidone ISM 100 mg.
Abbreviations: DB, double blind; PSP, Personal and Social Performance.
Figure 2 Mean domain scores of the Personal and Social Performance (PSP) scale at each assessment point during the double blind (DB) phase.

Figure 3 Mean change from baseline to each time point in Personal and Social Performance (PSP) scale total score during the open-label extension (OLE) phase.

Notes: Mean (95% CI) PSP score at baseline for unstable patients = 57.85 (55; 60), stabilized patients = 64.30 (63; 66) and stable patients = 72.03 (70; 74). P values are for intragroup comparisons at each time point from baseline (*p < 0.05; **p < 0.01; ***p < 0.0001). The three patient groups (unstable, stabilized and stable) contain pooled data from Risperidone ISM 75 mg + Risperidone ISM 100 mg.
Abbreviations: BL, baseline; CI, Confidence interval; OLE, open-label extension; PSP, Personal and Social Performance.
Figure 3 Mean change from baseline to each time point in Personal and Social Performance (PSP) scale total score during the open-label extension (OLE) phase.

Figure 4 Mean domain scores of the Personal and Social Performance (PSP) scale at each assessment point during the open-label extension (OLE) phase.

Notes: Graphs representing each of the 4 domain mean scores measured by the PSP scale. Smaller domain scores correspond to better functioning. P values are for intragroup comparison at each time point from baseline (*p < 0.05; **p < 0.01; ***p < 0.0001). The three patient groups (unstable, stabilized and stable) contain pooled data from Risperidone ISM 75 mg + Risperidone ISM 100 mg.
Abbreviations: PSP, Personal and Social Performance; OLE, open-label extension.
Figure 4 Mean domain scores of the Personal and Social Performance (PSP) scale at each assessment point during the open-label extension (OLE) phase.

Figure 5 Mean change from baseline to each time point in SWN-20 total score during the open-label extension (OLE) phase.

Notes: Mean (95% CI) SWN-20 score at baseline for unstable patients = 85.62 (82; 90), stabilized patients = 88.71 (87; 91) and stable patients = 94.10 (91; 97). P values are for intragroup comparisons at each time point from baseline (*p < 0.05; **p < 0.01). The three patient groups (unstable, stabilized and stable) contain pooled data from Risperidone ISM 75 mg + Risperidone ISM 100 mg.
Abbreviations: BL, baseline; CI, Confidence interval; OLE, open-label extension; SWN-20, 20-items scale Subjective Well-Being Under Neuroleptics Treatment.
Figure 5 Mean change from baseline to each time point in SWN-20 total score during the open-label extension (OLE) phase.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.